MX9701683A - Tratamiento terapeutico de enfermedades asociadas a clostridium difficile. - Google Patents

Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.

Info

Publication number
MX9701683A
MX9701683A MX9701683A MX9701683A MX9701683A MX 9701683 A MX9701683 A MX 9701683A MX 9701683 A MX9701683 A MX 9701683A MX 9701683 A MX9701683 A MX 9701683A MX 9701683 A MX9701683 A MX 9701683A
Authority
MX
Mexico
Prior art keywords
clostridium difficile
associated diseases
therapeutic treatment
difficile associated
colitis
Prior art date
Application number
MX9701683A
Other languages
English (en)
Other versions
MXPA97001683A (es
Inventor
Eileen F Bostwick
Robert A Hoerr
Original Assignee
Galagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galagen Inc filed Critical Galagen Inc
Publication of MXPA97001683A publication Critical patent/MXPA97001683A/es
Publication of MX9701683A publication Critical patent/MX9701683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

El tratamiento de enfermedades asociadas a CLOSTRIDIUM DIFFICILE, tales como CLOSTRIDIUM DIFFICILE COLITIS, colitis Pseudomembranosa y diarrea asociada con antibioticos al administrar un anticuerpo que tiene actividad específica contra CLOSTRIDIUM DIFFICICLE COLITIS y toxinas del mismo solas o combinacion con vancomicina, bacitracina o metronidazol se describe en la presente, así como composiciones farmacéuticas para las mismas.
MX9701683A 1994-09-06 1995-08-14 Tratamiento terapeutico de enfermedades asociadas a clostridium difficile. MX9701683A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30091894A 1994-09-06 1994-09-06
US300918 1994-09-06
PCT/US1995/010335 WO1996007430A1 (en) 1994-09-06 1995-08-14 Therapeutic treatment of clostridium difficile associated diseases

Publications (2)

Publication Number Publication Date
MXPA97001683A MXPA97001683A (es) 1997-06-01
MX9701683A true MX9701683A (es) 1997-06-28

Family

ID=23161155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701683A MX9701683A (es) 1994-09-06 1995-08-14 Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.

Country Status (8)

Country Link
US (1) US5773000A (es)
EP (1) EP0779819A1 (es)
JP (1) JPH10505358A (es)
AU (1) AU702405B2 (es)
CA (1) CA2197714A1 (es)
MX (1) MX9701683A (es)
NZ (1) NZ291659A (es)
WO (1) WO1996007430A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754270B2 (en) 1997-10-20 2002-11-07 Sanofi Pasteur Biologics, Llc Passive immunization against clostridium difficile disease
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
FR2778187B1 (fr) * 1998-04-30 2001-06-22 Sanofi Elf Procede de selection de souches bacteriennes
AU781027B2 (en) * 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
US6290946B1 (en) * 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6270755B1 (en) 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US7074454B1 (en) 1999-11-01 2006-07-11 Mucovax Holding B.V. Production of mammary secretion antibodies in farm animals
CA2314494A1 (en) 2000-05-02 2001-11-02 Geltex Pharmaceuticals, Inc. Anionic polymers as species specific antibacterial agents
EP1358331A2 (en) * 2001-02-09 2003-11-05 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Clostridium difficile vaccine
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
CA2492211A1 (en) * 2002-07-22 2004-01-29 Genzyme Corporation Poly(potassium and sodium styrene sulfonate), its manufacture and its uses
WO2004019907A1 (en) * 2002-08-29 2004-03-11 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
GB0306782D0 (en) * 2003-03-25 2003-04-30 Neutec Pharma Plc Treatment of infection due to clostridium difficile
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
ATE554782T1 (de) 2004-08-23 2012-05-15 Bharat Biotech Int Ltd Synergistische formulierung auf eukaryotischer basis gegen gastrointestinale erkrankungen
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US8709413B2 (en) 2006-12-13 2014-04-29 Michael R. Simon Treatment of celiac disease with IgA
US7597891B2 (en) * 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
US7794721B2 (en) * 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US20080145420A1 (en) * 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US8021645B2 (en) * 2006-12-13 2011-09-20 Simon Michael R Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
US8119104B2 (en) * 2006-12-13 2012-02-21 Michael R. Simon Treatment of celiac disease with IgA
US8313730B2 (en) * 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
CA2752815A1 (en) 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
BR122019017005B1 (pt) 2011-04-22 2022-03-29 Wyeth Llc Composições que se relacionam a uma toxina de clostridium difficile mutante
EP2806882B1 (en) 2012-01-23 2018-11-14 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
CN104254542A (zh) 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US20150050245A1 (en) * 2013-08-14 2015-02-19 Tntgamble, Inc. Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US10716850B2 (en) 2014-12-31 2020-07-21 Wellin, Inc. Anti-inflammatory factor retentate, method of isolation, and use
US9492374B2 (en) 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers
US10478493B2 (en) 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients
US20220096510A1 (en) 2018-08-17 2022-03-31 Universidad Andrés Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
WO2023099711A2 (en) 2021-12-02 2023-06-08 Bactolife A/S Single domain antibodies for prevention of clostridium difficile infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106618A (en) * 1987-07-02 1992-04-21 Stolle Research And Development Corporation Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease

Also Published As

Publication number Publication date
JPH10505358A (ja) 1998-05-26
NZ291659A (en) 2001-04-27
WO1996007430A1 (en) 1996-03-14
AU3325895A (en) 1996-03-27
EP0779819A1 (en) 1997-06-25
CA2197714A1 (en) 1996-03-14
AU702405B2 (en) 1999-02-18
US5773000A (en) 1998-06-30

Similar Documents

Publication Publication Date Title
MX9701683A (es) Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.
NO963378D0 (no) Behandling av antibiotisk assosiert diare
EP1421948A3 (en) Use of botulinum toxins for treating sweating in humans
ATE316794T1 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
CA2424242A1 (en) Methods for treating muscle injuries
AU5906398A (en) Dosage composition for nasal delivery and method of use of the same
ES2196092T3 (es) Composicion antibacteriana liposomica, de baja rigidez.
HU911188D0 (en) Preventive and curative medical preparation for treating diseases caused by clostridium defficile diarrhea and pseudomembranous bacteria
NZ514260A (en) A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections
TR200201744T2 (tr) Bitki hastalıklarının kontrol edilmesi için bacillus pumilus soyu
HK1014155A1 (en) Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
CA2566687A1 (en) The use of tiacumicin b in the treatment of antibiotic resistant staphylococcus or vancomycin-resistant enterococci infections
AU1809495A (en) Composition and method for preventing and treating inflammation with immunoglobulin a
NZ326061A (en) Otic microbial combinations
EP0802731A4 (en) PROPHYLACTIC TREATMENT OF ALLERGIC CONTACT DERMATITIS
AU4170197A (en) Pharmaceutical compounds
IL132933A0 (en) Composition for the treatment of diarrheal disease
AU8078187A (en) Glycopeptide antibiotics
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
AU682166B2 (en) Synergising association having an antagonist effect on NK1 and NK2 receptors
DE60034879D1 (en) Lantibiotikum
MX9708611A (es) Compuestos de dialquiltiacumicina.
AU2003290015A1 (en) Mastitis treatment
AU2002314056A1 (en) Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS